MCL1 and breast carcinoma: Montero et al. (2019) also found that Mcl-1 is a key driver of adaptive survival in tumors that treated with targeting therapies. They demonstrated that combination inhibition of Mcl-1 and RAF-MEK-ERK pathway yielded dramatic therapeutic activity (Sale et al., 2019; Montero et al., 2019) Oakes group found that Mcl-1 drives breast cancer invasion, and suggested that Mcl-1 inhibition could be used in combination with medicine targeting Src kinases to suppress TNBC metastasis (Young et al., 2016).